Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Withdrawn 2Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

Rituximab 21Cyclophosphamide 21fludarabine 12fludarabine phosphate 10pirtobrutinib 6obinutuzumab 6ibrutinib 6acalabrutinib 6Tacrolimus 6Mycophenolic Acid 6Melphalan 6Magnetic Resonance Spectroscopy 6Biopsy 6venetoclax 5tocilizumab 5X-Rays 5Whole-Body Irradiation 5Specimen Handling 5Prednisone 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Etoposide 5Doxorubicin 5Thiotepa 4Lenalidomide 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Cytarabine 4Bendamustine Hydrochloride 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Non-Hodgkin × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡